NCT03099330View on ClinicalTrials.gov

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Advanced Cancer
Interventions
DRUG

TQ-B3139

TQ-B3139 p.o. qd

Trial Locations (1)

510060

RECRUITING

Sun-Yat-Sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY